LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

Home・Stock List・Halozyme Therapeutics Inc

Halozyme Therapeutics Inc

Open

Sector Healthcare

58.55 2.61

Buy Sell

Overview

Share price change

24h

Current

Min

56.71

Max

59.32

Key metrics
By Trading Economics
Income	44M 137M
Sales	59M 290M
P/E Sector Avg	21.73 104.138
EPS	1.27
Profit margin	47.245
Employees	373
EBITDA	22M 143M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+27.96 upside

Market Stats
By TradingEconomics
Market Cap	582M 7B
Previous open	55.94
Previous close	58.55

News Sentiment

By Acuity

34%

66%

93 / 390 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

50.51 / 51.14 Support & Resistance

Halozyme Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

1 Nov 2024, 11:30 UTC

Peer Comparison

Price change

Halozyme Therapeutics Inc Forecast

Price Target

By TipRanks

27.96% upside

12 Months Forecast

Average 73.13 USD 27.96%

High 136 USD

Low 52 USD

Based on 10 Wall Street analysts offering 12 month price targets forHalozyme Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

10 ratings

Buy

Hold

Sell

Based on 10 analysts giving stock ratings to Halozyme Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

50.51 / 51.14Support & Resistance

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

93 / 390 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc. is a biopharma technology platform company. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine its ENHANZE drug delivery technology with the collaborators' compounds. The Company's lead enzyme, rHuPH20, is used to facilitate the delivery of injected drugs and fluids. The Company's approved product and its collaborators’ approved products and product candidates are based on rHuPH20, a patented recombinant human hyaluronidase enzyme. The Company's lead product, Hylenex recombinant, is a formulation of rHuPH20 that facilitates subcutaneous fluid administration for achieving hydration, to increase the dispersion and absorption of other injected drugs and, in subcutaneous urography, to improve resorption of radiopaque agents. Its pipeline products include Herceptin SC, HYQVIA, DARZALEX and others.